|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8950 EUR | +5.29% |
|
+0.34% | -34.38% |
| 18/06 | AB Science Secures US Patent for Prostate Cancer Therapy | MT |
| 18/06 | AB Science Secures New U.S. Patent for Masitinib |
Company Valuation: AB Science
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 895.3 | 332.2 | 180.9 | 57.55 | 66.59 | 66.59 | - |
| Change | - | - | -45.55% | -68.19% | 15.71% | 0% | - |
| Enterprise Value (EV) | 895.3 | 332.2 | 180.9 | 57.55 | 66.59 | 66.59 | 66.59 |
| Change | - | - | -45.55% | -68.19% | 15.71% | 0% | 0% |
| P/E | - | -24.4x | -17.8x | -5.88x | - | - | - |
| PBR | - | - | - | - | - | - | - |
| PEG | - | - | 0.6x | 0.2x | - | - | - |
| Capitalization / Revenue | 566x | - | 187x | 53.7x | 95.4x | 55.5x | 51.2x |
| EV / Revenue | 0x | - | 0x | 0x | 60.5x | 55.5x | 51.2x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | - | - | -0x | -0x | -11.1x | -10.2x | -10.4x |
| EV / FCF | - | - | -0x | - | -11.1x | -10.4x | -18.5x |
| FCF Yield | - | - | -9.52% | - | -4.08% | -9.61% | -5.41% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | - | -0.29 | -0.2 | -0.15 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 1.583 | - | 0.97 | 1.072 | 1.174 | 1.2 | 1.3 |
| EBITDA | - | - | -11.16 | -5.416 | - | - | - |
| EBIT 1 | - | - | -13.43 | -6.083 | 0.639 | -6.5 | -6.4 |
| Net income | - | -13.62 | -10.05 | -7.831 | - | - | - |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 19.6600 | 7.0900 | 3.5550 | 0.8820 | 0.8700 | 0.8700 | 0.8700 |
| Nbr of stocks (in thousands) | 45,540 | 46,861 | 50,891 | 65,248 | 76,539 | 76,539 | - |
| Announcement Date | 30/04/21 | 01/03/23 | 15/05/24 | 13/05/25 | 13/05/26 | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 50.8x | 4.75x | 19.31x | 2.94% | 28TCr | ||
| 22.45x | 3.1x | 11.03x | 1.75% | 6.63TCr | ||
| 16.49x | 2.08x | 7.14x | 2.71% | 823.69Cr | ||
| 10.18x | 5.26x | 8.1x | - | 813.09Cr | ||
| 21.9x | 6.55x | 17.91x | -.--% | 445.07Cr | ||
| 42.25x | 2.39x | 29.15x | 0.73% | 370.76Cr | ||
| 29.4x | 5.61x | 16.05x | - | 341.75Cr | ||
| 102.42x | - | - | -.--% | 257.58Cr | ||
| Average | 36.99x | 4.25x | 15.53x | 1.35% | 4.73TCr | |
| Weighted average by Cap. | 43.94x | 4.42x | 17.39x | 2.64% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- AB Stock
- A8D Stock
- Valuation AB Science
Select your edition
All financial news and data tailored to specific country editions
















